Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 16 , ISSUE 5 ( September-October, 2024 ) > List of Articles

REVIEW ARTICLE

Clinical Profile of Patients with Peripartum Cardiomyopathy: A Single-center Experience and Review of Literature

Pinky Mishra, Ritu Sharma, Ruchi Verma

Keywords : Echocardiography, Left ventricle ejection fraction, Peripartum cardiomyopathy, Pulmonary edema, Systolic dysfunction

Citation Information : Mishra P, Sharma R, Verma R. Clinical Profile of Patients with Peripartum Cardiomyopathy: A Single-center Experience and Review of Literature. J South Asian Feder Obs Gynae 2024; 16 (5):602-610.

DOI: 10.5005/jp-journals-10006-2497

License: CC BY-NC 4.0

Published Online: 23-10-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Aim and background: Peripartum cardiomyopathy (PPCM) refers to a heart failure secondary to systolic dysfunction with left ventricular ejection fraction <45%, with no known prior cardiac disease. The clinical features of PPCM overlaps with physiological symptoms of pregnancy, leading to its delayed diagnosis and increased morbidity and mortality. The aim of this case series and review of literature is to increase the awareness of general care physician and obstetricians to this rare clinical entity. Case description: This is a case series of 5 patients with PPCM. All the patients were young (aged 22–30 years). All five of them presented in their third trimester with features of congestive heart failure. The most common high-risk factor among all patients was hypertension. Bedside echocardiography revealed LV dilatation with left ventricle ejection fraction (LVEF) <45% suggestive of PPCM. Patients were managed by multidisciplinary team and active management of heart failure was done. Two out of five patients were delivered vaginally, while the rest three underwent cesarean section for different indications. One of the two patients delivered vaginally underwent cardiac arrest 2 hours post-delivery and could not be resuscitated. Four out of 5 patients survived. Three of them were discharged home with no other sequelae and recovered their left ventricular functions at variable time periods after delivery. One of these four patients had the longest duration of hospital stay of 3 months. She suffered two episodes of cardiac arrest post-delivery. Patient suffered the cerebrovascular injury and developed paraplegia. Physiotherapy and rehabilitation were started along with the heart failure medications and were discharged home on the same. Her left ventricular functions did not recovered even at 12 months follow-up. Conclusion: Association of preeclampsia in this condition warrants future research to ascertain if recovery of ventricular function and hence the recovery of patient is different when PPCM is not associated with preeclampsia and if the management also differs in both the scenarios. Clinical significance: Echocardiography remains the gold standard in diagnosing the condition and must be incorporated in the initial workup of patients presenting with features of heart failure in late third trimester and early postpartum period.


PDF Share
  1. Bouhaddoune Y, Hbali A, Aissaoui H, et al. Peripartum cardiomyopathy: Alluring challenge – Case series and review of literature. Pan Afr Med J 2021;40:119. DOI: 10.11604/pamj.2021.40.119.29168.
  2. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: A position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010;12(8):767–778. DOI: 10.1093/eurjhf/hfq120.
  3. Isezuo SA, Abubakar SA. Epidemiologic profile of peripartum cardiomyopathy in a tertiary care hospital. Ethn Dis 2007;17(2): 228–233. PMID: 17682350.
  4. Fett JD, Christie LG, Carraway RD, et al. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc 2005;80(12):1602–1606. DOI: 10.4065/80.12.1602.
  5. Kamiya CA, Kitakaze M, Ishibashi-Ueda H, et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders – Results from the Japanese Nationwide survey of peripartum cardiomyopathy. Circ J 2011;75(8):1975–1981. DOI: 10.1253/circj.CJ-10-1214.
  6. Pandit V, Shetty S, Kumar A, et al. Incidence and outcome of peripartum cardiomyopathy from a tertiary hospital in South India. Trop Doct 2009;39(3):168–169. DOI: 10.1258/td.2008.080353.
  7. Hilfiker-Kleiner D, Sliwa K. Pathophysiology and epidemiology of peripartum cardiomyopathy. Nat Rev Cardiol 2014;11(6):364–370. DOI: 10.1038/nrcardio.2014.37.
  8. Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy: Clinical characteristics and a comparison between early and late presentation. Circulation 2005;111(16):2050–2055. DOI: 10.1161/01.CIR.0000162478.36652.7E.
  9. Mielniczuk LM, Williams K, Davis DR, et al. Frequency of peripartum cardiomyopathy. Am J Cardiol 2006;97(12):1765–1768. DOI: 10.1016/j.amjcard.2006.01.039.
  10. Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J 2006;152(3):509–513. DOI: 10.1016/j.ahj.2006.02.008.
  11. Bello N, Rendon IS, Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy: A systematic review and meta-analysis. J Am Coll Cardiol 2013;62(18):1715–1723. DOI: 10.1016/j.jacc.2013.08.717.
  12. Afana M, Brinjikji W, Kao D, et al. Characteristics and in-hospital outcomes of peripartum cardiomyopathy diagnosed during delivery in the United States from the nationwide inpatient sample (NIS) database. J Card Fail 2016;22(7):512–519. DOI: 10.1016/j.cardfail.2016.02.008.
  13. Shahul S, Rhee J, Hacker MR, et al. Subclinical left ventricular dysfunction in preeclamptic women with preserved left ventricular ejection fraction: A 2D s peckle-tracking imaging study. Circ Cardiovasc Imaging 2012;5(6):734–739. DOI: 10.1161/CIRCIMAGING.112.973818.
  14. Melchiorre K, Sutherland GR, Baltabaeva A, et al. Maternal cardiac dysfunction and remodeling in women with preeclampsia at term. Hypertension 2011;57(1):85–93. DOI: 10.1161/HYPERTENSIONAHA.110.162321.
  15. Melchiorre K, Sutherland GR, Liberati M, et al. Preeclampsia is associated with persistent postpartum cardiovascular impairment. Hypertension 2011;58(4):709–715. DOI: 10.1161/HYPERTENSIONAHA.111.176537.
  16. Shahul S, Medvedofsky D, Wenger JB, et al. Circulating antiangiogenic factors and myocardial dysfunction in hypertensive disorders of pregnancy. Hypertension 2016;67(6):1273–1280. DOI: 10.1161/HYPERTENSIONAHA.116.07252.
  17. Ramadan H, Rana S, Mueller A, et al. Myocardial performance index in hypertensive disorders of pregnancy: The relationship between blood pressures and angiogenic factors. Hypertens Pregnancy 2017;36(2):161–167. DOI: 10.1080/10641955.2017.1280048.
  18. Lindley KJ, Conner SN, Cahill AG, et al. Impact of preeclampsia on clinical and functional outcomes in women with peripartum cardiomyopathy. Circ Heart Fail 2017;10(6):e003797. DOI: 10.1161/CIRCHEARTFAILURE.116.003797.
  19. McNamara DM, Elkayam U, Alharethi R, et al. Clinical outcomes for peripartum cardiomyopathy in North America: Results of the IPAC study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol 2015;66(8):905–914. DOI: 10.1016/j.jacc.2015.06. 1309.
  20. Haghikia A, Rontgen P, Vogel-Claussen J, et al. Prognostic implication of right ventricular involvement in peripartum cardiomyopathy: A cardiovascular magnetic resonance study. ESC Heart Fail 2015;2(4):139–149. DOI: 10.1002/ehf2.12059.
  21. Blauwet LA, Delgado-Montero A, Ryo K, et al. Right ventricular function in peripartum cardiomyopathy at presentation is associated with subsequent left ventricular recovery and clinical outcomes. Circ Heart Fail 2016;9(5):e002756. DOI: 10.1161/CIRCHEARTFAILURE.115. 002756.
  22. Honigberg MC, Givertz MM. Peripartum cardiomyopathy. BMJ 2019;364:k5287. DOI: 10.1136/bmj.k5287.
  23. Yang Y, Rodriguez JE, Kitsis RN. A microRNA links prolactin to peripartum cardiomyopathy. J Clin Invest 2013;123(5):1925–1927. DOI: 10.1172/JCI69286.
  24. Honigberg MC, Cantonwine DE, Thomas AM, et al. Analysis of changes in maternal circulating angiogenic factors throughout pregnancy for the prediction of preeclampsia. J Perinatol 2016;36(3):172–177. DOI: 10.1038/jp.2015.170.
  25. Arany Z, Foo SY, Ma Y, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 2008;451(7181):1008–1012. DOI: 10.1038/nature06613.
  26. Patten IS, Rana S, Shahul S, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 2012;485(7398):333–338. DOI: 10.1038/nature11040.
  27. Damp J, Givertz MM, Semigran M, et al. Relaxin-2 and soluble Flt1 levels in peripartum cardiomyopathy: Results of the multicenter IPAC study. J Am Coll Cardiol Heart Fail 2016;4(5):380–388. DOI: 10.1016/j.jchf.2016.01.004.
  28. Pearl W. Familial occurrence of peripartum cardiomyopathy. Am Heart J 1995;129:421–422. DOI: 10.1016/0002-8703(95)90032-2.
  29. Ware JS, Li J, Mazaika E, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med 2016;374(3):233–241. DOI: 10.1056/NEJMoa1505517.
  30. Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, et al. Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation 2019;140(1):31–41. DOI: 10.1161/CIRCULATIONAHA.118. 037934.
  31. Ware JS, Amor-Salamanca A, Tayal U, et al. Genetic etiology for alcohol-induced cardiac toxicity. J Am Coll Cardiol 2018;71(20):2293–2302. DOI: 10.1016/j.jacc.2018.03.462.
  32. Davis MB, Arany Z, McNamara DM, et al. Peripartum cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2020;75(2):207–221. DOI: 10.1016/j.jacc.2019.11.014.
  33. Fett JD. Earlier detection can help avoid many serious complications of peripartum cardiomyopathy. Future Cardiol 2013;9(6):809–816. DOI: 10.2217/fca.13.63.
  34. Tanous D, Siu SC, Mason J, et al. B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol 2010;56(15):1247–1253. DOI: 10.1016/j.jacc.2010.02.076.
  35. Honigberg MC, Givertz MM. Arrhythmias in peripartum cardiomyopathy. Card Electrophysiol Clin 2015;7(2):309–317. DOI: 10.1016/j. ccep.2015.03.010.
  36. Irizarry OC, Levine LD, Lewey J, et al. Comparison of clinical characteristics and outcomes of peripartum cardiomyopathy between African American and non-African American women. JAMA Cardiol 2017;2(11):1256–1260. DOI: 10.1001/jamacardio.2017. 3574.
  37. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur J Heart Fail 2017;19(9):1131–1141. DOI: 10.1002/ejhf.780.
  38. Kolte D, Khera S, Aronow WS, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: A nationwide population-based study. J Am Heart Assoc 2014;3(3):e001056. DOI: 10.1161/JAHA.114.001056.
  39. Goland S, Modi K, Bitar F, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail 2009;15(8):645–50. DOI: 10.1016/j.cardfail.2009.03.008.
  40. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016;37(27):2129–2200. DOI: 10.1093/eurheartj/ehw128.
  41. Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: A consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail 2015;17(6):544–558. DOI: 10.1002/ejhf.289.
  42. Enriquez AD, Economy KE, Tedrow UB. Contemporary management of arrhythmias during pregnancy. Circ Arrhythm Electrophysiol 2014;7(5):961– 967. DOI: 10.1161/CIRCEP.114.001517.
  43. Hanssens M, Keirse MJ, Vankelecom F, et al. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol 1991;78(1):128–135. PMID: 2047053.
  44. Shotan A, Widerhorn J, Hurst A, et al. Risks of angiotensin converting enzyme inhibition during pregnancy: Experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 1994;96(5):451–456. DOI: 10.1016/0002-9343(94)90172-4.
  45. Bozkurt B, Colvin M, Cook J, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: A scientific statement from the American Heart Association. Circulation 2016;134(23):e579–e646. DOI: 10.1161/CIR.0000000000000455.
  46. Bauersachs J, Arrigo M, Hilfifiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: Practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2016;18(9):1096–1105. DOI: 10.1002/ejhf.586.
  47. Zimmerman H, Bose R, Smith R, et al. Treatment of peripartum cardiomyopathy with mechanical assist devices and cardiac transplantation. Ann Thorac Surg 2010;89(4):1211–1217. DOI: 10.1016/j.athoracsur.2009.12.064.
  48. Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: A proof-of-concept pilot study. Circulation 2010;121(13):1465–1473. DOI: 10.1161/CIRCULATIONAHA.109.901496.
  49. Hilfiker-Kleiner D, Haghikia A, Nonhoff J, et al. Peripartum cardiomyopathy: Current management and future perspectives. Eur Heart J 2015;36(18):1090–1097. DOI: 10.1093/eurheartj/ehv009.
  50. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39(34):3165–3241. DOI: 10.1093/eurheartj/ehy340.
  51. Cooper LT, Mather PJ, Alexis JD, et al. Myocardial recovery in peripartum cardiomyopathy: Prospective comparison with recent onset cardiomyopathy in men and nonperipartum women. J Card Fail 2012;18(1):28–33. DOI: 10.1016/j.cardfail.2011.09.009.
  52. Biteker M, Ilhan E, Biteker G, et al. Delayed recovery in peripartum cardiomyopathy: An indication for long-term follow up and sustained therapy. Eur J Heart Fail 2012;14(8):895–901. DOI: 10.1093/eurjhf/hfs070.
  53. Haghikia A, Podewski E, Libhaber E, et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol 2013;108(4):366. DOI: 10.1007/s00395-013-0366-9.
  54. Felker GM, Jaeger CJ, Klodas E, et al. Myocarditis and long-term survival in peripartum cardiomyopathy. Am Heart J 2000;140(5): 785–791. DOI: 10.1067/mhj.2000.110091.
  55. Lidegaard O, Lokkegaard E, Svendsen AL, et al. Hormonal contraception and risk of venous thromboembolism: National follow-up study. BMJ 2009;339:b2890. DOI: 10.1136/bmj.b2890.
  56. Gemzell-Danielsson K, Rabe T, Cheng L. Emergency contraception. Gynecol Endocrinol 2013;29 Suppl 1:1–14. DOI: 10.3109/09513590.2013.774591.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.